Id: | acc0866 |
Group: | 2sens |
Protein: | beta-catenin |
Gene Symbol: | CTNNB1 |
Protein Id: | P35222 |
Protein Name: | CTNB1_HUMAN |
PTM: | phosphorylation |
Site: | Thr41 |
Site Sequence: | DSGIHSGATTTAPSLSGKGNP |
Disease Category: | Cancer |
Disease: | Hepatocellular Carcinoma |
Disease Subtype: | |
Disease Cellline: | HuH-7 |
Disease Info: | |
Drug: | Canagliflozin |
Drug Info: | "Canagliflozin is an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor used to improve glycemic control in adults with type 2 diabetes mellitus by reducing renal glucose reabsorption and promoting urinary glucose excretion, with a recommended initial dose of 100 mg once daily, which may be increased to 300 mg based on clinical response and renal function." |
Effect: | modulate |
Effect Info: | "CANA promotes the proteasomal degradation of beta-catenin protein by increasing the phosphorylation of beta-catenin, thereby inhibiting the growth of hepatocellular carcinoma." |
Note: | |
Score: | 4.0 |
Pubmed(PMID): | 31142735 |
Sentence Index: | 31142735_4-5 |
Sentence: | "Notably, we found that CANA treatment significantly downregulated the expression of beta-catenin in HCC cells in. By co-treating cells with cycloheximide and MG-132, we proved that CANA promoted proteasomal degradation of beta-catenin protein by increasing phosphorylation of beta-catenin, and CANA-induced inactivation of protein phosphatase 2A was identified being responsible for this effect." |
Sequence & Structure:
MATQADLMELDMAMEPDRKAAVSHWQQQSYLDSGIHSGATTTAPSLSGKGNPEEEDVDTSQVLYEWEQGFSQSFTQEQVADIDGQYAMTRAQRVRAAMFPETLDEGMQIPSTQFDAAHPTNVQRLAEPSQMLKHAVVNLINYQDDAELATRAIPELTKLLNDEDQVVVNKAAVMVHQLSKKEASRHAIMRSPQMVSAIVRTMQNTNDVETARCTAGTLHNLSHHREGLLAIFKSGGIPALVKMLGSPVDSVLFYAITTLHNLLLHQEGAKMAVRLAGGLQKMVALLNKTNVKFLAITTDCLQILAYGNQESKLIILASGGPQALVNIMRTYTYEKLLWTTSRVLKVLSVCSSNKPAIVEAGGMQALGLHLTDPSQRLVQNCLWTLRNLSDAATKQEGMEGLLGTLVQLLGSDDINVVTCAAGILSNLTCNNYKNKMMVCQVGGIEALVRTVLRAGDREDITEPAICALRHLTSRHQEAEMAQNAVRLHYGLPVVVKLLHPPSHWPLIKATVGLIRNLALCPANHAPLREQGAIPRLVQLLVRAHQDTQRRTSMGGTQQQFVEGVRMEEIVEGCTGALHILARDVHNRIVIRGLNTIPLFVQLLYSPIENIQRVAAGVLCELAQDKEAAEAIEAEGATAPLTELLHSRNEGVATYAAAVLFRMSEDKPQDYKKRLSVELTSSLFRTEPMAWNETADLGLDIGAQGEPLGYRQDDPSYRSFHSGGYGQDALGMDPMMEHEMGGHHPGADYPVDGLPDLGHAQDLMDGLPPGDSNQLAWFDTDL
Select PDB:
Target | Drug name | MOA | Phase | Status | Disease | Source |
---|---|---|---|---|---|---|
CTNNB1 | PRI-724 | CBP/beta catenin inhibitor | 2 | Withdrawn | colorectal adenocarcinoma | ClinicalTrials |
CTNNB1 | PRI-724 | CBP/beta catenin inhibitor | 2 | Recruiting | cirrhosis of liver | ClinicalTrials |
CTNNB1 | PRI-724 | CBP/beta catenin inhibitor | 1 | Completed | acute myeloid leukemia | ClinicalTrials |
CTNNB1 | PRI-724 | CBP/beta catenin inhibitor | 1 | Completed | chronic myelogenous leukemia | ClinicalTrials |
CTNNB1 | PRI-724 | CBP/beta catenin inhibitor | 1 | Terminated | neoplasm | ClinicalTrials |
CTNNB1 | PRI-724 | CBP/beta catenin inhibitor | 1 | Completed | pancreatic carcinoma | ClinicalTrials |
CTNNB1 | PRI-724 | CBP/beta catenin inhibitor | 1 | Completed | pancreatic adenocarcinoma | ClinicalTrials |
CTNNB1 | PRI-724 | CBP/beta catenin inhibitor | 1 | Completed | Malignant Pancreatic Neoplasm | ClinicalTrials |
Note: Only show clinically investigational or approved drugs with protein targets.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACCTNNB1-Thr41 | |
---|---|
Cancer | Intensity |
BRCA | |
COAD | |
HGSC | 0.385 |
ccRCC | |
GBM | 0.75 |
HNSC | |
LUAD | |
LUSC | |
non_ccRCC | |
PDAC | |
UCEC | -1.135 |
PTM-Disease Association:
source: PTMDResidue | Position | State | Disease | Class | PMID |
---|---|---|---|---|---|
T | 41 | D | Head and neck squamous cell carcinoma | Phosphorylation | 21281788 |
T | 41 | D | Retinoblastoma | Phosphorylation | 35968358 |
T | 41 | N | Colorectal cancer | Phosphorylation | 11955436 |
T | 41 | U | Colorectal cancer | Phosphorylation | 37369481 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.